Regen BioPharma reported continued progress in developing small molecule drugs that activate and inhibit NR2F6. The company reports that using a focused compound library and Regen's patented screening methodology, it has identified a dynamic new chemical compound series that modulates NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have identified a particularly active series of NR2F6 activators, which are not toxic and have an ability to activate NR2F6 approximately 10 times more effectively than seen with our previous series," Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen said. "Of particular interest is the parent structure that this series contains. It leads us to believe that we may now understand the structural basis for activating NR2F6."